FDA grants 510(k) approval for BioPlex 2200 Syphilis Total & RPR assay to diagnosis syphilis infection. Bio-Rad Laboratories
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, announced it has received FDA 510(k) clearance for its BioPlex 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection.
The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in Bio-Rad�s growing infectious disease menu for the BioPlex 2200 System, a fully automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or �multiplex� multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins